New letters urge the Centers for Medicare & Medicaid Services to expand Medicare and Medicaid to include FDA-approved ...

A report from The Lancet Diabetes & Endocrinology Commission has proposed new criteria for defining and diagnosing obesity, ...

New poll shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs if they are ...

New Rule Seeks to Expand Medicare and Medicaid Coverage of Weight Loss Drugs. The Biden Administration has proposed a new ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

The conversation surrounding health care reform has intensified in recent years, revealing deep divides in how we view personal responsibility, government intervention and public health ...

Its weight-loss drug policy would fall to Trump's pick for health secretary, Robert F Kennedy Jr, and Mehmet Oz, Trump's ...

In his first confirmation hearing, Robert F. Kennedy Jr. tried to distance himself from his past statements on abortion and ...

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...

Will Medicare end Novo Nordisk's obesity drug boom? It's not surprising that CMS chose Ozempic, Wegovy, and Rybelsus for Medicare drug price negotiations. Between November 2023 and October 2024 ...